Edgar Filing: Karnani Vikram - Form 4

Check this box if no longer subject to Section 16. SECURITIES STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. SECURITIES SECURITIES Number: 200 Estimated average burden hours per									3235-0287 January 31, 2005 iverage		
(Print or Type	Responses)										
Karnani Vikram Sy			Symbol	2. Issuer Name and Ticker or Trading Symbol Horizon Pharma plc [HZNP]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)	3. Date of	f Earliest Tr	ansaction	-		(Chec	ck all applicable)		
				onth/Day/Year) /31/2018				Director 10% Owner X Officer (give title Other (specify below) below) EVP, Chief Commercial Officer			
				nendment, Date Original (onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
DUBLIN, I								Form filed by M Person			
(City)	(State)	(Zip)	Tabl	le I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			d of (D)	Securities Beneficially Owned	Indirect (I)			
Ordinary	07/01/0010			Code V		(D)	Price		D		
Shares	07/31/2018			М	5,675	А	<u>(1)</u>	44,837 <u>(2)</u>	D		
Ordinary Shares	07/31/2018			F	1,663	D	\$ 17.63	43,174	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Karnani Vikram - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction of Derivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	<u>(1)</u>	07/31/2018		М	5,675	(3)	(3)	Ordinary Shares	5,675	\$

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Karnani Vikram C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE 1ST FLOOR, 1 BURLINGTON RD DUBLIN, L2 4			EVP, Chief Commercial Officer			
Signatures						

/s/ Miles W. McHugh, 08/01/2018 Attorney-in-Fact **Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. (1)
- Includes 2,371 ordinary shares of the Issuer acquired by the reporting person on June 1, 2018 pursuant to an employee stock purchase (2)program.
- Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% (3) annually on each anniversary of the vesting commencement date (July 31, 2014).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.